Journal ArticleOPEN ACCESS

The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria

  • Kim J
  • Lee J
  • Kim B
  • et al.
The Korean Journal of Hematology (2010) 45(4) 269
DOI: 10.5045/kjh.2010.45.4.269
N/ACitations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by chronic complement-mediated hemolysis. Eculizumab, a humanized monoclonal antibody against the terminal complement protein C5, potently reduces chronic intravascular hemolysis. We tested the clinical efficacy and safety of a 24-week treatment with eculizumab in 6 Korean patients with PNH.

Cite

CITATION STYLE

APA

Kim, J. S., Lee, J. W., Kim, B. K., Lee, J.-H., & Chung, J. (2010). The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. The Korean Journal of Hematology, 45(4), 269. https://doi.org/10.5045/kjh.2010.45.4.269

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free